Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Radiation.

University of Heidelberg, Heidelberg, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Heidelberg
Treatments:RadiationHospital:University of Heidelberg
Drugs:Journal:Link
Date:Jul 2012

Description:

This study involved elderly patients with anaplastic astrocytoma or glioblastoma who were divided into two separate treatment groups. Group A had 195 patients with a median age of 72 years (range of 66-84) and 45% were male. Group B had 178 patients with a median age of 71 years (range 66-82) and 49% male.

Treatment:
Patients in group A were treated with the chemotherapy agent temozolomide.
Group B patients were treated with radiotherapy.

Toxicities:
The most severe toxicities in group A were of grade 4 and included infection and blood clot.

The most severe toxicities in group B were of grade 4 and included infection and neurological disorders.

Results:
Median overall survival was 8.6 months in group A and 9.6 months in group B.

Support:
This study was funded by the pharmaceutical companies Merck Sharp and Dohme.

Correspondence: Dr. Wolfgang Wick; email: [email protected]



Back